Literature DB >> 3526216

Mathematic modeling of fetal growth: development of individual growth curve standards.

R L Deter, I K Rossavik, R B Harrist, F P Hadlock.   

Abstract

To provide a more precise means for monitoring individual fetal growth and to improve the detection of growth abnormalities, the Rossavik growth model [P = c(t)k + s(t)] has been used to establish individual growth curve standards. A longitudinal study of the growth of one-dimensional (biparietal diameter, head, and abdominal circumferences), two-dimensional (head and abdominal profile areas), and three-dimensional (head and abdominal volumes) parameters in 18 normal fetuses has revealed that the growth of all parameters can be well-described by the Rossavik model (R2: 97.2 to 99.5%). Strong statistical evidence was obtained indicating that the coefficient k is principally a geometric coefficient having a value determined primarily by the dimension of the parameter being studied. It was also found that the coefficients c and s can be estimated from the data obtained before 28 weeks' conceptual age. Individual growth curve models derived from data obtained before 28 weeks were capable of predicting growth beyond 28 weeks. These models provide growth curve standards for evaluating individual fetal growth beyond 28 weeks.

Entities:  

Mesh:

Year:  1986        PMID: 3526216

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  9 in total

1.  Methodological challenges in the study of fetal growth.

Authors:  T D Abell
Journal:  Hum Nat       Date:  1994-03

Review 2.  Individualized growth assessment: conceptual framework and practical implementation for the evaluation of fetal growth and neonatal growth outcome.

Authors:  Russell L Deter; Wesley Lee; Lami Yeo; Offer Erez; Uma Ramamurthy; Medha Naik; Roberto Romero
Journal:  Am J Obstet Gynecol       Date:  2018-02       Impact factor: 8.661

3.  Personalized third-trimester fetal growth evaluation: comparisons of individualized growth assessment, percentile line and conditional probability methods.

Authors:  Russell L Deter; Wesley Lee; Haleh Sangi-Haghpeykar; Adi L Tarca; Jia Li; Lami Yeo; Roberto Romero
Journal:  J Matern Fetal Neonatal Med       Date:  2015-09-25

4.  Fetal growth cessation in late pregnancy: its impact on predicted size parameters used to classify small for gestational age neonates.

Authors:  Russell L Deter; Wesley Lee; Haleh Sangi-Haghpeykar; Adi L Tarca; Lami Yeo; Roberto Romero
Journal:  J Matern Fetal Neonatal Med       Date:  2014-07-11

5.  A modified prenatal growth assessment score for the evaluation of fetal growth in the third trimester using single and composite biometric parameters.

Authors:  Russell L Deter; Wesley Lee; Haleh Sangi-Haghpeykar; Adi L Tarca; Lami Yeo; Roberto Romero
Journal:  J Matern Fetal Neonatal Med       Date:  2014-07-11

6.  Individualized fetal growth assessment: critical evaluation of key concepts in the specification of third trimester size trajectories.

Authors:  Russell L Deter; Wesley Lee; Haleh Sangi-Haghpeykar; Adi L Tarca; Lami Yeo; Roberto Romero
Journal:  J Matern Fetal Neonatal Med       Date:  2013-09-12

7.  The use of angiogenic biomarkers in maternal blood to identify which SGA fetuses will require a preterm delivery and mothers who will develop pre-eclampsia.

Authors:  Tinnakorn Chaiworapongsa; Roberto Romero; Amy E Whitten; Steven J Korzeniewski; Piya Chaemsaithong; Edgar Hernandez-Andrade; Lami Yeo; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2016

Review 8.  Defining normal and abnormal fetal growth: promises and challenges.

Authors:  Jun Zhang; Mario Merialdi; Lawrence D Platt; Michael S Kramer
Journal:  Am J Obstet Gynecol       Date:  2010-01-13       Impact factor: 8.661

9.  Small Size at Birth or Abnormal Intrauterine Growth Trajectory: Which Matters More for Child Growth?

Authors:  Jennifer A Hutcheon; Geir W Jacobsen; Michael S Kramer; Marit Martinussen; Robert W Platt
Journal:  Am J Epidemiol       Date:  2016-06-02       Impact factor: 4.897

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.